Skyhawk Therapeutics Names Aaron Deves as Chief Commercial Officer for SKY-0515 Launch

Skyhawk Therapeutics, a biotechnology firm focusing on RNA-targeting therapies for neurological diseases, has appointed Aaron Deves as Chief Commercial Officer. Deves, with over 30 years of experience, will lead the commercialization of SKY-0515, a potential treatment for Huntington's disease, aiming for a 2027 launch.

Deves's expertise includes launching therapies for neurological disorders, notably chorea in Huntington's disease. His previous roles at Teva Pharmaceuticals, Otsuka, and Pfizer highlight his extensive leadership in marketing and commercialization. Deves aims to make SKY-0515 widely accessible, contingent on further clinical success and regulatory approvals.

Skyhawk anticipates potential accelerated approval in Australia within the next year, followed by other markets in 2027. The appointment signals Skyhawk's commitment to addressing unmet needs in neurological conditions.